news
Pharmacology
Results 1 - 20 of 58.
Health - Pharmacology - 09.12.2024
MASH Discovery Redefines Subtypes with Distinct Risks : Shaping the Future of Fatty Liver Disease Treatment
MASH is a growing pandemic worldwide, with obesity and diabetes on the rise. It is also an area of significant unmet medical need. François Pattou Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), impacts roughly 30% of the global adult population.
Health - Pharmacology - 30.10.2024

Unsplash Teams from the departments of clinical and biological hematology, obstetrics and gynecology, pharmacovigilance, medical intensive care, infectiology, as well as the clinical research unit of theHôpital Cochin-Port Royal AP-HP, Université Paris Cité, Inserm and the HEMAPREG network, coordinated by Mr Pierre Pinson and Drs Ismael Boussaid and Rudy Birsen, have conducted a study on pregnancy-associated hematological cancers.
Health - Pharmacology - 15.10.2024
Resistance mutations to nirsevimab are rare in respiratory syncytial virus (RSV)
Nirsevimab is an antibody targeting the respiratory syncytial virus (RSV). Available in France since September 2023, it is indicated in neonates and infants for the prevention of bronchiolitis caused by RSV. AdobeStock Nirsevimab is an antibody targeting the respiratory syncytial virus (RSV). Available in France since September 2023, it is indicated in neonates and infants for the prevention of bronchiolitis caused by RSV.
Health - Pharmacology - 05.09.2024
Ebola: a study in Guinea reveals persistent immunity five years after vaccination
Epidemics of Ebola virus disease occur periodically in several sub-Saharan African countries. Two vaccines have already received WHO prequalification against the Ebolavirus Zaire species. However, information on the long-term immune response to these vaccines is still insufficient. We need to consolidate our knowledge on this subject to continue developing the safest and most effective vaccination strategies possible, for both adults and children.
Health - Pharmacology - 04.09.2024
A Parkinson’s treatment could delay progression of one of the forms of AMD
Age-related macular degeneration (AMD) is the leading cause of visual disability in people over 50 years of age. Age-related macular degeneration (AMD) is the leading cause of visual disability in people over 50 years of age. Improving the treatment offering for patients is a major challenge for research.
Pharmacology - Life Sciences - 27.08.2024

Scientists have deciphered the activation pathway of bemnifosbuvir 1 , a drug candidate initially in development to treat hepatitis C virus (HCV). The findings of the research team, led by CNRS scientists 2 , unlock new opportunities to boost the efficacy of this type of drug against other RNA viruses, such as the ones that cause Covid-19 and dengue fever.
Health - Pharmacology - 12.08.2024
Rapid rollout of smallpox vaccination reduces the risk of mpox
The ANRS DOXYVAC trial, promoted and funded by ANRS Emerging Infectious Diseases, and conducted by research teams from Inserm, AP-HP, Université Paris Cité and Sorbonne Université (France), shows that a rapid rollout of smallpox vaccination with MVA-BN ( Modified vaccine Ankara ) among HIV-positive men who have sex with men significantly reduces the risk of mpox by 99%.
Health - Pharmacology - 18.07.2024
A promising new therapeutic approach for patients with arteriovenous malformations
Phospho-ERK (red), Green Fluorescent Protein (cyan) and DAPI coimmunofluorescence on spleen sections from mice carrying a KRAS G12C endothelial mutation © Guillaume Canaud The teams of the translational medicine and targeted therapies unit of the Necker-Enfants Malades AP-HP hospital, Inserm, Paris Cité University within the Necker-Enfants Malades Institute, coordinated by professors Guillaume Canaud (Université Paris Cité, AP-HP) and Laurent Gu
Life Sciences - Pharmacology - 22.05.2024

A ground-breaking study conducted by INSERM's Groupe de Recherches sur l'Alcool et les Pharmacodépendances (GRAP) opens up new therapeutic perspectives for the treatment of alcohol addiction with psilocybin, the active compound in hallucinogenic mushrooms. Published in the scientific journal Brain , their work confirms the potential of psilocybin to combat alcohol addiction, while shedding light on the molecule's hitherto unknown mechanisms of action.
Health - Pharmacology - 21.05.2024
Tuberculosis: a new lead for biomarkers to assess the risk of transmission
Tuberculosis is the second leading cause of death from infectious disease in the world after COVID-19. Scientists from INRAE and Inserm have discovered two subsets of neutrophils that play opposing roles in inflammatory responses to infection and could serve as biomarkers to identify individuals at risk of developing a contagious form of the disease.
Health - Pharmacology - 13.05.2024
Cancer spread: targeting platelets to counter metastasis?
Scanning electron microscopy. Here we see how platelets (in blue/purple) attach to two tumour cells (in red) in a pre-clinical mouse model. Maria Jesus Garcia Leon (unit 1109 Inserm/Université de Strasbourg) What if our blood platelets , which play a major role in maintaining the integrity of our circulatory system, were not always on our side' Research teams from Inserm, Université de Strasbourg and the French Blood Establishment have studied their role in the process of metastasis formation.
Health - Pharmacology - 17.04.2024
Preventing cardiovascular risk thanks to a tool for measuring arterial stiffness
Cardiovascular diseases represent the leading cause of death worldwide . Preventing cardiovascular risk by identifying the people most susceptible to these diseases is a major public health challenge. In a new study in this field, researchers from Inserm, Université de Lorraine and Nancy Regional University Hospital opted to focus on arterial stiffness and how it changes with age, given that ageing is associated with a loss of arterial flexibility.
Health - Pharmacology - 10.04.2024

Inflammation plays a major role in allergic diseases, affecting at least 17 million people in France, including 4 million asthmatics. One of the molecules that initiates this process in the respiratory tract has just been identified. This molecule, a member of the alarmin family, is a major therapeutic target for the development of new treatments for respiratory allergies.
Health - Pharmacology - 11.03.2024

The WHO recently classified the Nipah virus (NiV) as one of the eight main emerging pathogens likely to cause major epidemics in the future. In a context where no treatment or vaccine is yet available, a team comprising researchers from Inserm (Unit 955-VRI) and from the Université Paris-Est Créteil (UPEC) is presenting the preclinical results of an innovative vaccine against this virus.
Health - Pharmacology - 15.02.2024

By studying for the first time the effects of chemotherapy on certain cells in the tumor microenvironment , a team from the Institut Curie and Inserm, led by Dr. Fatima Mechta-Grigoriou, has taken a major step towards understanding the mechanisms of chemotherapy resistance in ovarian cancer patients.
Health - Pharmacology - 24.11.2023

Adobe stock Currently, the treatment of heart valve diseases relies on the replacement of the dysfunctional valve with an artificial prosthesis. However, this procedure cannot be offered to all patients due to its invasive nature.
Pharmacology - Life Sciences - 28.08.2023

Difficulty staying awake may seem trivial, but it's the main symptom of one of the most severe sleep disorders: narcolepsy. In Montpellier, the Centre de référence des narcolepsies et hypersomnies rares (Inserm/University/CHU de Montpellier) headed by Yves Dauvilliers is conducting cutting-edge research into this disease.
Health - Pharmacology - 27.07.2023

Antibody fragments of EPCT112 bNAb (blue) discovered at the Institut Pasteur by Hugo Mouquet's team, here forming a complex with the HIV-1 envelope protein (Env) (shown in yellow and orange Some HIV-1 carriers who have received an early antiretroviral treatment during several years are able to control the virus for a long term after treatment interruption.
Health - Pharmacology - 11.07.2023

To understand the main determinants behind worldwide antibiotic resistance dynamics, scientists from the Institut Pasteur, Inserm, Université de Versailles Saint-Quentin-en-Yvelines and Université Paris-Saclay developed a statistical model based on a large-scale spatial-temporal analysis. Using the ATLAS antimicrobial resistance surveillance database, the model revealed significant differences in trends and associated factors depending on bacterial species and resistance to certain antibiotics.
Health - Pharmacology - 23.05.2023

In 2020, in the midst of the COVID-19 crisis, we spoke with Franck Zal, a doctor in marine biology from Sorbonne University and founder of the company Hemarina. At the time, HEMO2life - their flagship product created from the hemoglobin of the marine worm, the arenicole - was envisaged to improve the oxygenation of patients suffering from acute respiratory distress syndrome.